Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study

Journal of Clinical Hypertension

Volumn 18, Issue 2, 2016, Pages 121-128

  Lin, Chongting ^a   Zhang, Qing ^b   Zhang, Huifang ^a   Lin, Aixia ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; PLACEBO; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BREAST TENDERNESS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; GYNECOMASTIA; HEART ARREST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HEART RATE VARIABILITY; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; INCIDENCE; LONG TERM SURVIVAL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SUDDEN CARDIAC DEATH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VASCULAR ENDOTHELIUM; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DOSE RESPONSE; DRUG MONITORING; HEART FUNCTION TEST; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; LONG TERM ADVERSE EFFECTS; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HEART FUNCTION TESTS; HUMANS; KIDNEY FAILURE, CHRONIC; LONG TERM ADVERSE EFFECTS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENAL DIALYSIS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84958527800     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12628     Document Type: Article

References (32)

1. Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014;13:823-833.
2. Power A. Stroke in dialysis and chronic kidney disease. Blood Purif. 2013;36:179-183.
3. Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol. 2014;10:174-180.
4. Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528-536.
5. Pelliccia F, Rosano G, Patti G, et al. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension. Int J Cardiol 2015;200:8-11.
6. Flevari P, Kalogeropoulou S, Drakou A, et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens. 2013;31:1239-1244.
7. Ni X, Zhang J, Zhang P, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens (Greenwich). 2014;16:658-663.
8. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009;119:671-679.
9. Lee MJ, Doh FM, Kim CH, et al. Interdialytic weight gain and cardiovascular outcome in incident hemodialysis patients. Am J Nephrol. 2014;39:427-435.
10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
11. Schumm J, Greulich S, Wagner A, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson. 2014;16:14.
12. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010-2019.
13. Takasaki K, Miyata M, Imamura M, et al. Left ventricular dysfunction assessed by cardiac time interval analysis among different geometric patterns in untreated hypertension. Circ J. 2012;76:1409-1414.
14. Hwang MH, Yoo JK, Luttrell M, et al. Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci (Lond). 2013;125:513-520.
15. Inrig JK, Van Buren P, Kim C, et al. Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. Clin J Am Soc Nephrol. 2012;7:1300-1309.
16. Korkmaz H, Onalan O. Evaluation of endothelial dysfunction: flow-mediated dilation. Endothelium. 2008;15:157-163.
17. Atkinson G, Batterham AM, Thijssen DH, et al. A new approach to improve the specificity of flow-mediated dilation for indicating endothelial function in cardiovascular research. J Hypertens. 2013;31:287-291.
18. Chen JY, Tsai SH, Chuang PH, et al. A comorbidity index for mortality prediction in Chinese patients with ESRD receiving hemodialysis. Clin J Am Soc Nephrol. 2014;9:513-519.
19. Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med. 2007;357:1229-1237.
20. Saudan P, Mach F, Perneger T, et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant. 2003;18:2359-2363.
21. Yongsiri S, Thammakumpee J, Prongnamchai S, et al. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients. Ther Apher Dial. 2015;19:81-86.
22. Matsumoto Y, Kageyama S, Yakushigawa T, et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology. 2009;114:32-38.
23. Hung SC, Lin YP, Huang HL, et al. Aldosterone and mortality in hemodialysis patients: role of volume overload. PLoS One. 2013;8:e57511.
24. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700-2706.
25. Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int. 2009;75:771-773.
26. Bomback AS, Klemmer PJ. Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif. 2012;33:119-124.
27. Hirsch JS, Drexler Y, Bomback AS. Aldosterone blockade in chronic kidney disease. Semin Nephrol. 2014;34:307-322.
28. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, et al. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart. 2013;99:320-326.
29. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
30. Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1380-1387.
31. Michea L, Vukusich A, Gonzalez M, et al. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int. 2004;66:1647-1653.
32. Zhang L, Hao JB, Ren LS, et al. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Lab Invest. 2014;94:839-850.